Phentolamine Ophthalmic Solution 0.75%

DRUG5 trials

Sponsors

Ocuphire Pharma, Inc.

Conditions

DilationDim Light Vision DisturbancesMydriasisPresbyopia

Phase 2

Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia

CompletedNCT04675151

Ocuphire Pharma, Inc.Presbyopia

Start: 2021-02-15End: 2021-06-30Updated: 2025-10-10

Phase 3

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis

CompletedNCT04620213

Ocuphire Pharma, Inc.Dilation, Mydriasis

Start: 2020-11-18End: 2021-03-15Updated: 2023-09-11

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances

CompletedNCT04638660

Ocuphire Pharma, Inc.Dim Light Vision Disturbances

Start: 2020-12-30End: 2022-05-19Updated: 2025-10-14

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

CompletedNCT05134974

Ocuphire Pharma, Inc.Dilation, Mydriasis

Start: 2021-11-18End: 2022-03-29Updated: 2023-08-29

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

CompletedNCT05223478

Ocuphire Pharma, Inc.Dilation, Mydriasis

Start: 2021-12-17End: 2022-04-28Updated: 2023-09-05

Related Papers

A randomized phase 2 clinical trial of phentolamine mesylate eye drops in patients with severe night vision disturbances.

2022-10-083 citations